Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...
The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.
The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...
High-potassium foods: As mentioned earlier, potassium helps your body excrete excess sodium, reducing water retention and ...
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...
Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...
Findings seen for patients with type 2 diabetes during a 5-year period. (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...